Trial
NCT00801060
Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Biogen
Collaborators
—
Condition
Chronic Lymphocytic Leukemia
Intervention
Lumiliximab + FCR
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-10-02